What Can a Prenuvo Whole-Body MRI Find, and Does Screening Healthy People Help?

Prenuvo, Inc. sells a Whole Body Scan, and its own scan page describes it as a radiation-free MRI.¹ The pages carry no date. The scan page says the brain and vascular portion "May help identify structural abnormalities, changes in brain tissue, or vascular findings such as aneurysms or other irregularities".¹ The FAQ states: "Our Prenuvo screening scans are designed to be performed completely without IV-contrast."² The claim tested here has three parts. The scan is radiation-free and non-contrast. It screens for hundreds of conditions. Those conditions include early solid tumors, brain aneurysms and fatty liver disease. Prenuvo's scan page lists many organ-by-organ findings the scan "may" help identify. The phrase "hundreds of conditions" does not appear on that page or the FAQ, but Prenuvo's homepage says the scan helps "screen for hundreds of conditions across major organ systems". The homepage gives no list of those conditions and no accuracy data.¹

I have a Prenuvo scan every year and pay for it myself. Prenuvo had no part in this piece and has not seen it.

The description mostly holds. The scan uses no radiation and no contrast, and Prenuvo builds it to look for tumors, aneurysms and liver fat. The "hundreds" wording does not appear on the scan page or the FAQ, but it does appear on Prenuvo's homepage as marketing copy.¹,² What the record does not show is that looking helps. The only FDA clearance found in Prenuvo's name is K242825 for body composition software. Prenuvo's pages also describe add-on brain and heart analyses as FDA-cleared, apparently third-party software. No clearance of the whole-body screening scan itself was found.³ A letter by Prenuvo employees reports that a 2025 meta-analysis of opportunistic whole-body MRI found a pooled confirmed cancer detection rate of 1.57 percent. The meta-analysis was not reviewed here, and one of its included cohorts came from Prenuvo-affiliated authors. The figure covers opportunistic whole-body MRI generally, not Prenuvo's scan alone.⁹ A 2019 review of whole-body MRI studies in general concluded that false positives appear to be substantial. It is not specific to Prenuvo's protocol.⁶ No study in the sources reviewed shows that screening people without symptoms reduces illness or death, and the Canadian Association of Radiologists says there is no compelling evidence from high-quality studies.⁵

What does Prenuvo say the scan looks for?

The scan page lists findings the scan "may" help identify, organ by organ. For the brain and blood vessels that includes aneurysms.¹ The same page lists a cheaper Focused scan and states "Arms, spine, and aneurysm assessment not included". Aneurysm detection is therefore not part of every Prenuvo product.¹ The scan page reviewed for this piece does not use the phrase "hundreds of conditions", but the Prenuvo homepage does. The homepage carries the wording as marketing. It gives no list of the conditions and no performance data for them.¹

The FAQ uses aneurysm and fatty liver language. It does not attach validated performance figures to either.² The same FAQ concedes that the scan does not replace guideline screening. It says the scan is less sensitive for colon polyps and is not dedicated breast imaging.² In Prenuvo's own words, then, it does not substitute for colonoscopy or mammography.²

What has the FDA actually cleared?

On January 17, 2025, the FDA cleared 510(k) K242825 for a product called Prenuvo Body Composition.³ The indications for use describe it as "a software medical device (SaMD) which is intended for non-invasive fat, muscle and organ quantification."³ That is software that measures fat and tissue from MRI data. It is not a clearance of the whole-body screening service, and it makes no claim about cancer, aneurysms or fatty liver screening.³ A 510(k) finding of substantial equivalence is also not FDA approval. No clearance of the screening scan itself turned up in the search. That is an absence in the search, not proof that none exists.³

How often does the scan find cancer?

In December 2025, three Prenuvo employees published a letter in European Radiology about a 2025 meta-analysis of opportunistic whole-body MRI. They declared their employment in the letter.⁹ The letter accepts the meta-analysis figure: "a pooled confirmed cancer detection rate of 1.57% (95% CI 1.22–2.03%), which they describe as 'modest'".⁹ That is roughly 16 confirmed cancers per 1,000 people scanned. The letter also notes that the included studies did not formally assess incidental findings or cost-effectiveness.⁹ The meta-analysis itself was not reviewed for this piece.

How often is a finding wrong?

Kwee and Kwee pooled 12 studies covering 5,373 asymptomatic adults in the Journal of Magnetic Resonance Imaging in November 2019.⁶ Their conclusion: "Verification data are lacking. The proportion of false-positive findings appears to be substantial."⁶ Six of the 12 studies reported false-positive findings. Their pooled proportion was 16.0 percent, with a confidence interval from 1.9 to 65.8 percent. Heterogeneity between studies was very high, with I² from 95.6 to 99.1. The review rated its level of evidence at 4. It is not specific to Prenuvo.⁶

Gibson and colleagues published a meta-analysis in The BMJ on November 22, 2018. It covered 32 studies and 27,643 participants, most of them on brain-only MRI at 1.5 tesla.⁷ Eight studies imaged brain and body. In those, the pooled rate of potentially serious incidental findings was 3.9 percent, with a confidence interval from 0.4 to 27.1 percent.⁷ Across the whole review, follow-up data on what happened to people after a finding covered only 234 participants. The authors wrote: "A substantial proportion of apparently asymptomatic adults will have potentially serious incidental findings on MRI, but little is known of their health consequences."⁷

What is the 99.8 percent figure?

Prenuvo's FAQ cites a negative predictive value of 99.8 percent. The figure is the company's own. No independent verification of it turned up in the sources reviewed.² The December 2025 letter by Prenuvo's own staff describes a roughly 99.8 percent figure in one of their cohorts as "a proxy metric rather than a formal diagnostic NPV". The letter adds that the full analysis of that cohort had not yet been peer-reviewed.⁹ The sources do not confirm that the letter's figure and the FAQ's figure are the same number.²,⁹

Has anyone shown that screening healthy people helps?

Not yet. Prenuvo's own prospective study, the Hercules Project, was published online as a trial-in-progress abstract for the 2025 ASCO Annual Meeting on May 28, 2025.⁸ It is registered as NCT06212479 and plans 12 to 18 months of follow-up. Ten of its 11 authors are Prenuvo staff. The Pragmatic arm is self-funded, and a Health Equity arm plans subsidised access for 10 to 50 percent of the cohort. The abstract reports no results.⁸ On August 25, 2026, Cochrane published a protocol for a review of whole-body MRI or CT screening in asymptomatic adults. It aims "to evaluate the benefits and harms" against no intervention, usual care or other strategies. It is a protocol and has no findings.¹⁰

What do radiology bodies say?

On April 17, 2023, the American College of Radiology said it "does not believe there is sufficient evidence to justify recommending total body screening for patients with no clinical symptoms, risk factors or a family history suggesting underlying disease or serious injury."⁴ The statement is short, predates later Prenuvo-linked data, and says the college will continue to monitor studies.⁴

The Canadian Association of Radiologists approved a policy statement in June 2025.⁵ It reads: "There is no compelling evidence from high-quality studies demonstrating that whole-body MRI screening in asymptomatic individuals improves long-term health outcomes, reduces morbidity or mortality, or leads to better health at the population level."⁵ Part of its argument concerns capacity in Canada's public health system. Its remark that full-body MRI is not optimized for any condition is general, not a review of Prenuvo's protocol.⁵